CTLA-4 can function as a negative regulator of T cell activation

CTLA-4 is a second receptor for the B cell activation antigen B7.

Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685 · see citing works

Identification of a monoclonal antibody specific for a murine T3 polypeptide.

Léo, O., Foo, M., Sachs, D. H., Samelson, L. E., & Bluestone, J. A. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.5.1374 · Cited by 1,596 · see citing works

CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones

Harding, F., McArthur, J. G., Gross, J. A., Raulet, D. H., & Allison, J. P. (1992) · Nature · doi:10.1038/356607a0 · Cited by 1,558 · see citing works

A new member of the immunoglobulin superfamily—CTLA-4

Brunet, J., Denizot, F., Luciani, M., Roux-Rouquié, M., Suzan, M., Mattéi, M., & Golstein, P. (1987) · Nature · doi:10.1038/328267a0 · Cited by 1,307 · see citing works

The B7 and CD28 receptor families

June, C. H., Bluestone, J. A., Nadler, L. M., & Thompson, C. B. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90080-9 · Cited by 1,296 · see citing works

Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors.

Unkeless, J. C. (1979) · The Journal of Experimental Medicine · doi:10.1084/jem.150.3.580 · Cited by 1,271 · see citing works

Differential T Cell Costimulatory Requirements in CD28-Deficient Mice

Shahinian, A., Pfeffer, K., Lee, K. P., Kündig, T. M., Kishihara, K., Wakeham, A. C., Kawai, K., Ohashi, P. S., Thompson, C. B., & Mak, T. W. (1993) · Science · doi:10.1126/science.7688139 · Cited by 1,258 · see citing works

Long-Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA4lg

Lenschow, D. J., Zeng, Y., Thistlethwaite, J. R., MONTAG, A. G., Brady, W., Gibson, M. G., Linsley, P. S., & Bluestone, J. A. (1992) · Science · doi:10.1126/science.1323143 · Cited by 1,121 · see citing works

B70 antigen is a second ligand for CTLA-4 and CD28

Azuma, M., Ito, D., Yagita∥, H., Okumura, K., Phillips, J. H., Lanier, L. L., & Somoza, C. (1993) · Nature · doi:10.1038/366076a0 · Cited by 910 · see citing works

Cloning of B7-2: a CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation

Freeman, G. J., Gribben, J. G., Boussiotis, V. A., Ng, J. W., Restivo, V. A., Lombard, L. A., Gray, G. S., & Nadler, L. M. (1993) · Science · doi:10.1126/science.7694363 · Cited by 903 · see citing works

Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation Molecule

Linsley, P. S., Wallace, P. M., Johnson, J., Gibson, M. G., Greene, J. L., Ledbetter, J. A., Singh, C., & Tepper, M. A. (1992) · Science · doi:10.1126/science.1496399 · Cited by 790 · see citing works

Positive and negative selection of an antigen receptor on T cells in transgenic mice

Sha, W. C., Nelson, C. A., Newberry, R. D., Kranz, D. M., Russell, J. H., & Loh, D. Y. (1988) · Nature · doi:10.1038/336073a0 · Cited by 743 · see citing works

Role of the CD28 receptor in T-cell activation

June, C. H., Ledbetter, J. A., Linsley, P. S., & Thompson, C. B. (1990) · Immunology Today · doi:10.1016/0167-5699(90)90085-n · Cited by 674 · see citing works

Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.

Linsley, P. S., Greene, J. L., Tan, P., Bradshaw, J., Ledbetter, J. A., Anasetti, C., & Damle, N. K. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.176.6.1595 · Cited by 581 · see citing works

Monoclonal antibodies to mouse MHC antigens. III. Hybridoma antibodies reacting to antigens of the H-2b haplotype reveal genetic control of isotype expression.

Ozato, K., & Sachs, D. H. (1981) · The Journal of Immunology · doi:10.4049/jimmunol.126.1.317 · Cited by 572 · see citing works

A monoclonal antibody discriminating between subsets of T and B cells.

BRUCE, J. S., Symington, F. W., McKearn, T. J., & Sprent, J. (1981) · The Journal of Immunology · doi:10.4049/jimmunol.127.6.2496 · Cited by 542 · see citing works

T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo.

Turka, L. A., Linsley, P. S., Lin, H., Brady, W., Leiden, J. M., Wei, R. Q., Gibson, M. L., Zheng, X. G., Myrdal, S. E., & Gordon, D. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.11102 · Cited by 533 · see citing works

Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion.

Lin, H., Bolling, S. F., Linsley, P. S., Wei, R. Q., Gordon, D., Thompson, C. B., & Turka, L. A. (1993) · The Journal of Experimental Medicine · doi:10.1084/jem.178.5.1801 · Cited by 485 · see citing works

CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location

Harper, K., Balzano, C., Rouvier, É., Mattéi, M., Luciani, M., & Golstein, P. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.3.1037 · Cited by 432 · see citing works

Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production.

Freeman, G. J., Borriello, F., Hodes, R. J., Reiser, H., Gribben, J. G., Ng, J. W., Kim, J., Goldberg, J. M., Hathcock, K. S., & László, G. (1993) · The Journal of Experimental Medicine · doi:10.1084/jem.178.6.2185 · Cited by 351 · see citing works

CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes.

Azuma, M., Cayabyab, M. J., Buck, D., Phillips, J. H., & Lanier, L. L. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.175.2.353 · Cited by 319 · see citing works

Characterization of CTLA-4 structure and expression on human T cells.

Lindsten, T., Lee, K. P., Harris, E. S., Petryniak, B., Craighead, N., Reynolds, P. J., Lombard, D. B., Freeman, G. J., Nadler, L. M., Gray, G. S., et al. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.7.3489 · Cited by 316 · see citing works

A naturally occurring peptide recognized by alloreactive CD8+ cytotoxic T lymphocytes in association with a class I MHC protein

Udaka, K., Tsomides, T. J., & Eisen, H. N. (1992) · Cell · doi:10.1016/0092-8674(92)90617-l · Cited by 280 · see citing works

Expression and functional significance of an additional ligand for CTLA-4.

Lenschow, D. J., Su, G. H., Zuckerman, L. A., Nabavi, N., Jellis, C. L., Gray, G. S., Miller, J., & Bluestone, J. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.11054 · Cited by 259 · see citing works

Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells.

Razi-Wolf, Z., Freeman, G. J., Galvin, F., D, B. B. M., Nadler, L. M., & Reiser, H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.9.4210 · Cited by 210 · see citing works

Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes.

Kranz, D. M., Tonegawa, S., & Eisen, H. N. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.24.7922 · Cited by 177 · see citing works

CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production

Freeman, G. J., Lombard, D. B., Gimmi, C. D., et al. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.12.3795 · Cited by 150 · see citing works

B cell function in mice transgenic for mCTLA4-H gamma 1: lack of germinal centers correlated with poor affinity maturation and class switching despite normal priming of CD4+ T cells.

Lane, P. J. L., Burdet, C., Hubele, S., Scheidegger, D., Müller, U., McConnell, F. M., & Kosco‐Vilbois, M. H. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.179.3.819 · Cited by 129 · see citing works

CD28 engagement by B7/BB-1 induces transient down-regulation of CD28 synthesis and prolonged unresponsiveness to CD28 signaling

Linsley, P. S., Bradshaw, J., Urnes, M., et al. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.8.3161 · Cited by 115 · see citing works

Costimulation of T lymphocytes with integrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 induces functional expression of CTLA-4, a second receptor for B7.

Damle, N. K., Klussman, K., Leytze, G., Myrdal, S. E., Aruffo, A. A., Ledbetter, J. A., & Linsley, P. S. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.6.2686 · Cited by 87 · see citing works

Disparate interaction of peptide ligand with nascent versus mature class I major histocompatibility complex molecules: comparisons of peptide binding to alternative forms of Ld in cell lysates and the cell surface.

Smith, J. D., Lie, W., Gorka, J., et al. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.175.1.191 · Cited by 83 · see citing works

Human CD28 and CTLA-4 Ig superfamily genes are located on chromosome 2 at bands q33?q34

Lafage‐Pochitaloff, M., Costello, R. T., Couez, D., Simonetti, J., Mannoni, P., Mawas, C. E., & Olive, D. (1990) · Immunogenetics · doi:10.1007/bf00211556 · Cited by 79 · see citing works

T90/44 (9.3 antigen). A cell surface molecule with a function in human T cell activation

Lesslauer, W., Koning, F., Ottenhoff, T. H. M., Giphart, M. J., Goulmy, E., & van Rood, J. J. (1986) · European Journal of Immunology · doi:10.1002/eji.1830161017 · Cited by 56 · see citing works

Internalization of a major group human rhinovirus does not require cytoplasmic or transmembrane domains of ICAM-1

Staunton, D. E., Gaur, A., Chan, P. Y., & Springer, T. A. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.10.3271 · Cited by 51 · see citing works

A TCR Cell Recognizing a Novel TL-encoded Gene ProductPreprint

Houlden, B. A., Matis, L. A., Cron, R. Q., Widacki, S. M., Brown, G., Pampeno, C. L., Meruelo, D., & Bluestone, J. A. (1989) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1989.054.01.006 · Cited by 50 · see citing works

The future of immune checkpoint therapy

Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · see citing works

A guide to cancer immunotherapy: from T cell basic science to clinical practice

Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154 · see citing works

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914 · see citing works

Lymphoproliferative Disorders with Early Lethality in Mice Deficient in <i>Ctla-4</i>

Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766 · see citing works

CD28/B7 SYSTEM OF T CELL COSTIMULATION

Lenschow, D. J., Walunas, T. L., & Bluestone, J. A. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.233 · Cited by 2,717 · see citing works

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential

Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345 · see citing works

Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance

Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189 · see citing works

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · see citing works

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4

Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233 · see citing works

Regulatory T cells in cancer immunotherapy

Tanaka, A., & Sakaguchi, S. (2017) · Cell Research · doi:10.1038/cr.2016.151 · Cited by 1,860 · see citing works

Small-molecule inhibitors of protein–protein interactions: progressing towards the dream

Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705 · see citing works

Cancer regression and autoimmunity induced by cytotoxic t lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575 · see citing works

ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28

Hutloff, A., Dittrich, A. M., Beier, K. C., Eljaschewitsch, B., Kraft, R., Anagnostopoulos, I., & Kroczek, R. A. (1999) · Nature · doi:10.1038/16717 · Cited by 1,482 · see citing works

Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade

Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302 · see citing works

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy

Gide, T. N., Quek, C., Menzies, A. M., Tasker, A. T., Shang, P., Holst, J., Madore, J., Lim, S. Y., Velickovic, R., Wongchenko, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.003 · Cited by 1,047 · see citing works

Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4

Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012 · see citing works

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008 · see citing works

CD28 Costimulation: From Mechanism to Therapy

Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A., & Bluestone, J. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.020 · Cited by 937 · see citing works

CD28 and CTLA-4 coreceptor expression and signal transduction

Rudd, C. E., Taylor, A., & Schneider, H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00770.x · Cited by 898 · see citing works

Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells

Selby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srinivasan, M., & Korman, A. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0013 · Cited by 857 · see citing works

Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4

Beck, K. E., Blansfield, J. A., Tran, K. Q., Feldman, A. L., Hughes, M. S., Royal, R. E., Kammula, U. S., Topalian, S. L., Sherry, R. M., Kleiner, D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5716 · Cited by 833 · see citing works

Deubiquitination and Stabilization of PD-L1 by CSN5

Lim, S.-O., Li, C.-W., Xia, W., Cha, J.-H., Chan, L.-C., Wu, Y., Chang, S.-S., Lin, W.-C., Hsu, J.-M., Hsu, Y.-H., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.010 · Cited by 793 · see citing works

Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody

Iwama, S., De Remigis, A., Callahan, M. K., Slovin, S. F., Wolchok, J. D., & Caturegli, P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008002 · Cited by 715 · see citing works

Molecular Basis of T Cell Inactivation by CTLA-4

Lee, K.-M., Chuang, E., Griffin, M., Khattri, R., Hong, D. K., Zhang, W., Straus, D., Samelson, L. E., Thompson, C. B., & Bluestone, J. A. (1998) · Science · doi:10.1126/science.282.5397.2263 · Cited by 684 · see citing works

Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade

Downey, S. G., Klapper, J. A., Smith, F. O., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Allen, T. E., Levy, C. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0187 · Cited by 624 · see citing works

Regulation of T Cell Receptor Signaling by Tyrosine Phosphatase SYP Association with CTLA-4

Marengère, L. E. M., Waterhouse, P., Duncan, G. S., Mittrücker, H.-W., Feng, G.-S., & Mak, T. W. (1996) · Science · doi:10.1126/science.272.5265.1170 · Cited by 551 · see citing works

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment

Spranger, S., Koblish, H. K., Horton, B., Scherle, P. A., Newton, R., & Gajewski, T. F. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-3 · Cited by 552 · see citing works

Genomic correlates of response to immune checkpoint blockade

Keenan, T. E., Burke, K. P., & Van Allen, E. M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0382-x · Cited by 448 · see citing works

STING: a master regulator in the cancer-immunity cycle

Zhu, Y., An, X., Zhang, X., Qiao, Y., Zheng, T., & Li, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1087-y · Cited by 431 · see citing works

Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo

Read, S., Greenwald, R., Izcue, A., Robinson, N., Mandelbrot, D., Francisco, L., Sharpe, A. H., & Powrie, F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4376 · Cited by 434 · see citing works

Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling.

Rudd, C. E., & Schneider, H. (2003) · Nature Reviews Immunology · doi:10.1038/nri1131 · Cited by 392 · see citing works

T Cell Exhaustion

Baessler, A., & Vignali, D. A. A. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-090222-110914 · Cited by 420 · see citing works

Intrinsic and extrinsic control of peripheral T‐cell tolerance by costimulatory molecules of the CD28/ B7 family

Bour‐Jordan, H., Esensten, J. H., Martinez‐Llordella, M., Penaranda, C., Stumpf, M., & Bluestone, J. A. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01011.x · Cited by 391 · see citing works

Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers

Sharma, A., Subudhi, S. K., Blando, J., Scutti, J., Vence, L., Wargo, J., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0762 · Cited by 382 · see citing works

The immune system and cancer evasion strategies: therapeutic concepts

Muenst, S., Läubli, H., Soysal, S. D., Zippelius, A., Tzankov, A., & Hoeller, S. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12470 · Cited by 304 · see citing works

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy

Fan, X., Quezada, S. A., Sepulveda, M. A., Sharma, P., & Allison, J. P. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20130590 · Cited by 300 · see citing works

The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti–CTLA-4 Therapy

Fu, T., He, Q., & Sharma, P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1138 · Cited by 243 · see citing works

Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms

Moslehi, J., Lichtman, A. H., Sharpe, A. H., Galluzzi, L., & Kitsis, R. N. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145186 · Cited by 237 · see citing works

Cell membrane coated-nanoparticles for cancer immunotherapy

Zeng, Y., Li, S., Zhang, S., Wang, L., Yuan, H., & Hu, F. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.023 · Cited by 238 · see citing works

Anti-CTLA-4 therapy results in higher CD4 ⁺ ICOS ^hi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues

Chen, H., Liakou, C. I., Kamat, A., Pettaway, C., Ward, J. F., Tang, D. N., Sun, J., Jungbluth, A. A., Troncoso, P., Logothetis, C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813175106 · Cited by 218 · see citing works

Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma

Lussier, D. M., Johnson, J. L., Hingorani, P., & Blattman, J. N. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0067-z · Cited by 206 · see citing works

Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy

Ng Tang, D., Shen, Y., Sun, J., Wen, S., Wolchok, J. D., Yuan, J., Allison, J. P., & Sharma, P. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0020 · Cited by 203 · see citing works

Cytotoxic T lymphocyte-associated molecule-4, a high avidity receptor for CD80 and CD86, contains an intracellular localization motif in its cytoplasmic tail

Leung, H. T., Bradshaw, J., Cleaveland, J. S., & Linsley, P. S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.42.25107 · Cited by 191 · see citing works

Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells

Dovedi, S. J., Elder, M. J., Yang, C., Sitnikova, S. I., Irving, L., Hansen, A., Hair, J., Jones, D. C., Hasani, S., Wang, B., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1445 · Cited by 186 · see citing works

Antigen Presentation by Vascular Cells

Pober, J. S., Merola, J., Liu, R., & Manes, T. D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01907 · Cited by 165 · see citing works

CD28‐mediated induction of proliferation in resting T cells <i>in vitro</i> and <i>in vivo</i> without engagement of the T cell receptor: Evidence for functionally distinct forms of CD28

Tacke, M., Hanke, G., Hanke, T., & Hünig, T. (1997) · European Journal of Immunology · doi:10.1002/eji.1830270136 · Cited by 163 · see citing works

CD28: a signalling perspective

WARD, S. G. (1996) · Biochemical Journal · doi:10.1042/bj3180361 · Cited by 149 · see citing works

Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues

Bailey, C. M., Liu, Y., Liu, M., Du, X., Devenport, M., Zheng, P., Liu, Y., & Wang, Y. (2022) · Journal of Clinical Investigation · doi:10.1172/jci150846 · Cited by 151 · see citing works

Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its Management with Infliximab

Johnston, R. L., Lutzky, J., Chodhry, A., & Barkin, J. S. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-008-0641-z · Cited by 135 · see citing works

CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions

Laurent, S., Carrega, P., Saverino, D., Piccioli, P., Camoriano, M., Morabito, A., Dozin, B., Fontana, V., Simone, R., Mortara, L., et al. (2010) · Human Immunology · doi:10.1016/j.humimm.2010.07.007 · Cited by 121 · see citing works

Regulation of Cytotoxic T Lymphocyte-Associated Molecule-4 by Src Kinases

Chuang, E., Lee, K.-M., Robbins, M. D., Duerr, J. M., Alegre, M.-L., Hambor, J. E., Neveu, M. J., Bluestone, J. A., & Thompson, C. B. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.3.1270 · Cited by 119 · see citing works

Targeting the immune microenvironment in acute myeloid leukemia: a focus on T cell immunity

Lamble, A. J., & Lind, E. F. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00213 · Cited by 119 · see citing works

Gastrointestinal toxicity of immune checkpoint inhibitors: From mechanisms to management

Samaan, M. A., Pavlidis, P., Papa, S., Powell, N., & Irving, P. M. (2018) · Nature Reviews Gastroenterology &amp; Hepatology · doi:10.1038/nrgastro.2018.14 · Cited by 100 · see citing works

Induction of Cytotoxic T Lymphocyte Antigen 4 (Ctla-4) <u>Restricts</u> Clonal Expansion of Helper T Cells

Doyle, A. M., Mullen, A. C., Villarino, A. V., Hutchins, A. S., High, F. A., Lee, H. W., Thompson, C. B., & Reiner, S. L. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.7.893 · Cited by 102 · see citing works

Negative co-stimulation constrains T cell differentiation by imposing boundaries on possible cell states

Wei, S. C., Sharma, R., Anang, N.-A. A. S., Levine, J. H., Zhao, Y., Mancuso, J. J., Setty, M., Sharma, P., Wang, J., Pe’er, D., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.004 · Cited by 97 · see citing works

CTLA-4 Ligation Suppresses CD28-induced NF-κB and AP-1 Activity in Mouse T Cell Blasts

Olsson, C., Riebeck, K., Dohlsten, M., & Michaëlsson, E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.20.14400 · Cited by 84 · see citing works

T Cell Receptor-Interacting Molecule Acts as a Chaperone to Modulate Surface Expression of the CTLA-4 Coreceptor

Valk, E., Leung, R., Kang, H., Kaneko, K., Rudd, C. E., & Schneider, H. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.024 · Cited by 78 · see citing works

Tyrosine Phosphatase SHP-2 Binding to CTLA-4: Absence of Direct YVKM/YFIP Motif Recognition

Schneider, H., & Rudd, C. E. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2234 · Cited by 78 · see citing works

Pulsatile MEK inhibition improves anti-tumor immunity and T cell function in murine Kras mutant lung cancer

Choi, H., Deng, J., Li, S., Silk, T., Dong, L., Brea, E. J., Houghton, S., Redmond, D., Zhong, H., Boiarsky, J., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.066 · Cited by 72 · see citing works

LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures

Gestermann, N., Saugy, D., Martignier, C., Tillé, L., Fuertes Marraco, S. A., Zettl, M., Tirapu, I., Speiser, D. E., & Verdeil, G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1736792 · Cited by 69 · see citing works

Decreased proliferative capacity and increased susceptibility to activation-induced cell death in late-passage human cd4+ tcr2+ cultured T cell clones

Pawelec, G., Sansom, D., Rehbein, A., Adibzadeh, M., & Beckman, I. (1996) · Experimental Gerontology · doi:10.1016/s0531-5565(96)00097-6 · Cited by 68 · see citing works

Src Family Tyrosine Kinases Associate with and Phosphorylate CTLA-4 (CD152)

Miyatake, S., Nakaseko, C., Umemori, H., Yamamoto, T., & Saito, T. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9191 · Cited by 65 · see citing works

Long-term culture of monoclonal human T lymphocytes: models for immunosenescence?

Adibzadeh, M., Pohla, H., Rehbein, A., & Pawelec, G. (1995) · Mechanisms of Ageing and Development · doi:10.1016/0047-6374(95)01625-a · Cited by 64 · see citing works

Tremelimumab-Induced Graves Hyperthyroidism

Gan, E. H., Mitchell, A. L., Plummer, R., Pearce, S., & Perros, P. (2017) · European Thyroid Journal · doi:10.1159/000464285 · Cited by 58 · see citing works

Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors

Roy, D., Gilmour, C., Patnaik, S., & Wang, L. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1264327 · Cited by 53 · see citing works

Immunotherapies for pediatric cancer: current landscape and future perspectives

Hutzen, B., Paudel, S. N., Naeimi Kararoudi, M., Cassady, K. A., Lee, D. A., & Cripe, T. P. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09819-z · Cited by 44 · see citing works

Overcoming immunological tolerance to melanoma: targeting CTLA-4

HODI, F. S. (2010) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2010.01271.x · Cited by 36 · see citing works

Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response

Felix, J., Lambert, J., Roelens, M., Maubec, E., Guermouche, H., Pages, C., Sidina, I., Cordeiro, D. J., Maki, G., Chasset, F., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1136045 · Cited by 32 · see citing works

Regulation of CD28 expression on CD8+ T cells by CTLA-4

Berg, M., & Zavazava, N. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0107065 · Cited by 29 · see citing works

Modulation of amplitude and direction ofin vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens

Kim, J. J., Trivedi, N. N., Nottingham, L. K., Morrison, L. D., Tsai, A., Hu, Y., Mahalingam, S., Dang, K., Ahn, L., Doyle, N. K., et al. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199803)28:03 · Cited by 238 · see citing works

Dysregulated Expression of Both the Costimulatory CD28 and Inhibitory CTLA-4 Molecules in PB T Cells of Advanced Cervical Cancer Patients Suggests Systemic Immunosuppression Related to Disease Progression

Kosmaczewska, A., Boćko, D., Ciszak, L., Włodarska−Polińska, I., Kornafel, J. A., Szteblich, A., Masternak, A., & Frydecka, I. (2011) · Pathology & Oncology Research · doi:10.1007/s12253-011-9471-y · Cited by 38 · see citing works

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · see citing works

A quantitative analysis of antigen-presenting cell function: activated B cells stimulate naive CD4 T cells but are inferior to dendritic cells in providing costimulation.

Cassell, D. J., & Schwartz, R. H. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.180.5.1829 · Cited by 133 · see citing works